Search details
1.
Generation of evidence-based carboplatin dosing guidelines for neonates and infants.
Br J Cancer
; 129(11): 1773-1779, 2023 11.
Article
in English
| MEDLINE | ID: mdl-37816842
2.
A Phase 1/2 trial of SRA737 (a Chk1 inhibitor) administered orally in patients with advanced cancer.
Br J Cancer
; 129(1): 38-45, 2023 07.
Article
in English
| MEDLINE | ID: mdl-37120671
3.
A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma.
Br J Cancer
; 129(5): 811-818, 2023 09.
Article
in English
| MEDLINE | ID: mdl-37488446
4.
A Population Pharmacokinetic Modelling Approach to Unravel the Complex Pharmacokinetics of Vincristine in Children.
Pharm Res
; 39(10): 2487-2495, 2022 Oct.
Article
in English
| MEDLINE | ID: mdl-35986122
5.
Clinical utility of vinblastine therapeutic drug monitoring for the treatment of infantile myofibroma patients: A case series.
Pediatr Blood Cancer
; 69(7): e29722, 2022 07.
Article
in English
| MEDLINE | ID: mdl-35441483
6.
Sodium Thiosulfate for Protection from Cisplatin-Induced Hearing Loss.
N Engl J Med
; 378(25): 2376-2385, 2018 Jun 21.
Article
in English
| MEDLINE | ID: mdl-29924955
7.
Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom.
Br J Clin Pharmacol
; 87(2): 256-262, 2021 02.
Article
in English
| MEDLINE | ID: mdl-32519769
8.
Investigating current practices in renal function measurement and carboplatin dosing in children with cancer - a UK perspective.
Pediatr Hematol Oncol
; 37(3): 235-244, 2020 Apr.
Article
in English
| MEDLINE | ID: mdl-31941404
9.
Preclinical evaluation of the first intravenous small molecule MDM2 antagonist alone and in combination with temozolomide in neuroblastoma.
Int J Cancer
; 144(12): 3146-3159, 2019 06 15.
Article
in English
| MEDLINE | ID: mdl-30536898
10.
A novel imaging flow cytometry method for the detection of histone H4 acetylation in myeloid cells.
Eur J Clin Invest
; 49(7): e13115, 2019 Jul.
Article
in English
| MEDLINE | ID: mdl-30929275
11.
Pharmacodynamic Therapeutic Drug Monitoring for Cancer: Challenges, Advances, and Future Opportunities.
Ther Drug Monit
; 41(2): 142-159, 2019 04.
Article
in English
| MEDLINE | ID: mdl-30883508
12.
The use of pharmacokinetically guided carboplatin chemotherapy in a pre-term infant with neuroblastoma-associated spinal cord compression.
Pediatr Blood Cancer
; 66(9): e27825, 2019 09.
Article
in English
| MEDLINE | ID: mdl-31135092
13.
Fundamental problems with pediatric adaptive dosing of carboplatin using nuclear-medicine-based estimates of renal function.
Pediatr Blood Cancer
; 66(6): e27672, 2019 06.
Article
in English
| MEDLINE | ID: mdl-30767382
14.
Spontaneous fractures during 13-cis retinoic acid therapy for neuroblastoma.
Pediatr Blood Cancer
; : e30430, 2023 May 27.
Article
in English
| MEDLINE | ID: mdl-37243423
15.
The role of solute carrier (SLC) transporters in actinomycin D pharmacokinetics in paediatric cancer patients.
Eur J Clin Pharmacol
; 74(12): 1575-1584, 2018 Dec.
Article
in English
| MEDLINE | ID: mdl-30167756
16.
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.
Lancet Oncol
; 18(10): 1397-1410, 2017 10.
Article
in English
| MEDLINE | ID: mdl-28882536
17.
Personalization of dexamethasone therapy in childhood acute lymphoblastic leukaemia.
Br J Haematol
; 173(1): 13-24, 2016 Apr.
Article
in English
| MEDLINE | ID: mdl-26729065
18.
Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer.
Br J Clin Pharmacol
; 81(5): 989-98, 2016 May.
Article
in English
| MEDLINE | ID: mdl-26727248
19.
Investigating the Experiences of Childhood Cancer Patients and Parents Participating in Optional Nontherapeutic Clinical Research Studies in the UK.
Pediatr Blood Cancer
; 63(7): 1193-7, 2016 07.
Article
in English
| MEDLINE | ID: mdl-26928983
20.
Combination p53 activation and BCL-xL/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemia.
Leukemia
; 2024 Apr 10.
Article
in English
| MEDLINE | ID: mdl-38600316